Molecularly, melanomas harbor somatic ‘driver mutations’ that are mutually exclusive: 50% present gain‐of‐function BRAF mutations, while another 25% exhibit NRAS mutations (Cancer Genome Atlas Network, 2015). Here, BRAF is linked to melanoma.